Cell Signaling Technology

Product Pathways - Apoptosis / Autophagy

SignalSilence® Bcl-2 siRNA (Human Specific) #6441

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells 48 hours following mock transfection, transfection with nonspecific (control) siRNA (#6201) or transfection with Bcl-2 siRNA. Bcl-2 was detected using Bcl-2 Antibody #2872 and p42 was detected using p42 MAPK Antibody #9108. The Bcl-2 Antibody confirms silencing of Bcl-2 expression, and the p42 MAPK Antibody is used to control for protein loading and siRNA specificity.

Fluorescent Detection

Fluorescent Detection

Fluorescent detection of SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 in living HeLa cells 24 hours post-transfection, demonstrating nearly 100% transfection efficiency.

Directions for Use

CST recommends transfection with 100 nM SignalSilence® Bcl-2 siRNA (Human Specific). Decreased Bcl-2 expression was observed 24-72 hours post-transfection. See Protocol for transfection procedure.

Background

Bcl-2 exerts a survival function in response to a wide range of apoptotic stimuli through inhibition of mitochondrial cytochrome c release (1). It has been implicated in modulating mitochondrial calcium homeostasis and proton flux (2). Several phosphorylation sites have been identified within Bcl-2 including Thr56, Ser70, Thr74 and Ser87 (3). It has been suggested that these phosphorylation sites may be targets of the ASK1/MKK7/JNK1 pathway, and that phosphorylation of Bcl-2 may be a marker for mitotic events (4,5). Mutation of Bcl-2 at Thr56 or Ser87 inhibits its anti-apoptotic activity during glucocorticoid-induced apoptosis of T lymphocytes (6). Interleukin 3 and JNK-induced Bcl-2 phosphorylation at Ser70 may be required for its enhanced antiapoptotic functions (7).

Silencing Bcl-2 expression by RNA interfence induces p-53 depedent apoptosis (8).

  1. Murphy, K.M. et al. (2000) Cell Death Differ. 7, 102-111.
  2. Zhu, L. et al. (1999) J. Biol. Chem. 274, 33267-33273.
  3. Maundrell, K. et al. (1997) J. Biol. Chem. 272, 25238-25242.
  4. Yamamoto, K. et al. (1999) Mol. Cell. Biol. 19, 8469-8478.
  5. Ling, Y.H. et al. (1998) J. Biol. Chem. 273, 18984-18991.
  6. Huang, S.J. and Cidlowski, J.A. (2002) FASEB J. 16, 825-832.
  7. Deng, X. et al. (2001) J. Biol. Chem. 276, 23681-23688.
  8. Jiang, M. and Milner, J. (2003) Gene Dev. 17(7) , 832-837.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.

This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures.

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes